Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how ...

Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the company announced its partnership with Express Scripts Holding ...

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that as part of the ...

Express Scripts, one of the leading prescription-benefits managers in the US, is partnering with a compounding pharmacy to provide a $1-per-pill version of the drug that Turing Pharmaceuticals charges ...

When a generic drug formulation goes from $13.50 per pill to $750 each, the company making it is essentially putting a "Kick Me" sign on their back. But unless you've been offline or away from the ...

Imprimis Pharmaceuticals Inc IMMY wants to stop egregious drug pricing issues, and Mallinckrodt PLC MNK is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt ...

SAN DIEGO, Feb. 10, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded ...

NEW YORK (Reuters) - Imprimis Pharmaceuticals Inc (IMMY.O), the compounding pharmacy that makes a $1 copycat of Turing Pharmaceuticals' high priced Daraprim treatment, sees an opportunity to build a ...

Jan 16 (Reuters) - The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye ...

SAN DIEGO, July 23, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development ...